Trial · NCT07692295
Biomarkers for Post-treatment Control in HIV: International Study of the EU2Cure Research Consortium (Phase I)
NCT07692295, Not yet recruiting, Erasmus Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Biomarkers for Post-treatment Control in HIV: International Study of the EU2Cure Research Consortium (Phase I). Trials, record NCT07692295. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07692295
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Biomarkers for Post-treatment Control in HIV: International Study of the EU2Cure Research Consortium (Phase I)
- NCT number
- NCT07692295
- Status
- Not yet recruiting
- Enrollment
- 200 participants, estimated
- Lead sponsor
- Erasmus Medical Center
- Conditions
- HIV
- Interventions
- No Intervention: Observational Cohort
- First posted
- 2026-07-09
- Last updated
- 2026-07-09
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Intact proviral HIV DNA reservoir size in PTC and PIC before and during ATI | 1 year | Reservoir size will be measured as intact proviral HIV DNA and reported as log copies per 10\^6 CD4+ cells. Reservoir size in PTC, PIC, and NC before and after ATI will be described according to data distribution. |
| Primary | Total integrated HIV DNA reservoir size in PTC and PIC before and during ATI | 1 year | Reservoir size will be measured as total integrated HIV DNA and reported as log copies per 10\^6 PBMC. Reservoir size in PTC, PIC, and NC before and after ATI will be described according to data distribution. |
| Primary | Inducible HIV reservoir size in PTC and PIC before and during ATI | 1 year | Reservoir size will be measured as inducible HIV and reported as log HIV RNA or HIV DNA copies. Reservoir size in PTC, PIC, and NC before and after ATI will be described according to data distribution. |
| Primary | Time from the start of ATI until first measurement of HIV RNA >50 copies/mL in PTC and PIC. | 1 year | A survival analysis will be done for all PTC, PIC and NC who have been sourced from ATI trials. Baseline will be set as the start of the treatment interruption. Time will be noted in weeks until first measurement of HIV-RNA \>50 copies/mL for all study participants. Levels correspond to elite controller definition (Deeks \& Walker, 2007), PTC definition, and level below which HIV onward transmission rarely occurs (Gray et al., 2001). Analysis is by Kaplan Meier and Cox Proportional Hazard models with loss of viral control as event. Independent variables can be timing of ART initiation, duration of ART, HIV cure intervention (if any), demographic parameters (sex, age, place of birth, country of residence), viral dynamics (subtype, reservoir size) and immune characteristics (cd4+ count, cd8+ count, cd4/cd8 ratio). |
| Primary | Time from the start of ATI until first measurement of HIV RNA >400 copies/mL in PTC and PIC. | 1 year | A survival analysis will be done for all PTC, PIC and NC who have been sourced from ATI trials. Baseline will be set as the start of the treatment interruption. Time will be noted in weeks until first measurement of HIV-RNA \>400 copies/mL for all study participants. Levels correspond to elite controller definition (Deeks \& Walker, 2007), PTC definition, and level below which HIV onward transmission rarely occurs (Gray et al., 2001). Analysis is by Kaplan Meier and Cox Proportional Hazard models with loss of viral control as event. Independent variables can be timing of ART initiation, duration of ART, HIV cure intervention (if any), demographic parameters (sex, age, place of birth, country of residence), viral dynamics (subtype, reservoir size) and immune characteristics (cd4+ count, cd8+ count, cd4/cd8 ratio). |
| Primary | Time from the start of ATI until first measurement of HIV RNA > 1000 copies/mL in PTC and PIC. | 1 year | A survival analysis will be done for all PTC, PIC and NC who have been sourced from ATI trials. Baseline will be set as the start of the treatment interruption. Time will be noted in weeks until first measurement of HIV-RNA \>1000 copies/mL for all study participants. Levels correspond to elite controller definition (Deeks \& Walker, 2007), PTC definition, and level below which HIV onward transmission rarely occurs (Gray et al., 2001). Analysis is by Kaplan Meier and Cox Proportional Hazard models with loss of viral control as event. Independent variables can be timing of ART initiation, duration of ART, HIV cure intervention (if any), demographic parameters (sex, age, place of birth, country of residence), viral dynamics (subtype, reservoir size) and immune characteristics (cd4+ count, cd8+ count, cd4/cd8 ratio). |
| Primary | Number and severity of adverse events during and after ATI. | 1 year | Medical events in PTC, PIC and NC recorded in the clinical file will be described using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. If medical events have been reported using varied terminology in the ATI trials, two separate evaluators will reclassify them using CTCAE v5.0 terminology. In instances of conflicting classifications, an impartial researcher will make the final determination. |
| Primary | Biobank with samples from PTC, PIC and NC including sampling time points and material available. | 1 year from screening | Available samples will be indexed from previously performed ATI trials. An inventory will be made of the number of samples, type, volume, time of sampling, sampling technique and storage medium. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07692295
GET https://conductscience.org/api/trials/v1/NCT07692295/registered